edotreotide has been researched along with Lung Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
| Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Buck, AK; Herrmann, K; Kropf, S; Lapa, C; Lückerath, K; Pelzer, T; Rudelius, M; Samnick, S; Schirbel, A; Schmid, JS; Schoene, A; Wester, HJ | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R; Venkitaraman, B | 1 |
| Dutta, R; Jindal, T; Kumar, A; Kumar, R; Malhotra, A; Meena, M; Venkitaraman, B | 1 |
| Cornelissen, C; Frechen, D; Krüger, S; Kweider, S; Temur, Y | 1 |
| Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Kahn, D; Karwal, M; Madsen, M; Menda, Y; Miller, S; O'Dorisio, S; O'Dorisio, T; Ponto, J; Squires, S; Walkner, W | 1 |
| Buitrago, C; Herrmann, R; Maecke, H; Mueller-Brand, J; Pless, M; Waldherr, C | 1 |
| Bockisch, A; Broelsch, CE; Frilling, A; Hofmann, M; Mueller-Brand, J; Saner, F; Weber, F | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Waldherr, C | 1 |
| Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM | 1 |
2 review(s) available for edotreotide and Lung Neoplasms
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes | 2000 |
4 trial(s) available for edotreotide and Lung Neoplasms
| Article | Year |
|---|---|
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2014 |
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Topics: Adult; Aged; Amino Acids; Arginine; Carcinoid Tumor; Female; Humans; Infusions, Intravenous; Kidney; Lung Neoplasms; Lysine; Male; Meningioma; Middle Aged; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Topics: Aged; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes | 2004 |
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Lutetium; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes | 2006 |
6 other study(ies) available for edotreotide and Lung Neoplasms
| Article | Year |
|---|---|
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Topics: Adult; Aged; Coordination Complexes; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Receptors, CXCR4; Receptors, Somatostatin; Small Cell Lung Carcinoma | 2016 |
Role of 68Ga-DOTATOC PET/CT in carcinoids.
Topics: Carcinoid Tumor; Cushing Syndrome; Humans; Lung Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
Topics: Adolescent; Adult; Carcinoid Tumor; Female; Gallium Radioisotopes; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Topics: Adolescent; Adult; Carcinoid Tumor; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Middle Aged; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
[Neuroendocrine pulmonary neoplasms: improved diagnosis by DOTATOC- vs. FDG-PET/CT].
Topics: Biopsy; Bone Neoplasms; Carcinoma, Neuroendocrine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lumbar Vertebrae; Lung; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Octreotide; Positron-Emission Tomography; Ribs; Sacrum; Spinal Neoplasms; Tomography, X-Ray Computed | 2011 |
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Topics: Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Paraplegia; Radiopharmaceuticals; Somatostatin; Spinal Cord Compression; Spinal Neoplasms; Thoracic Vertebrae; Yttrium Radioisotopes | 2000 |